Tuttle Capital Management’s Gilead Sciences GILD Stock Holding History

Tuttle Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,338	Closed	-$337K	–	213
2020 Q3	$337K	Buy	+5,338	New	+$370K	0.23%	93
2017 Q3	–	Sell	-4,819	Closed	-$341K	–	77
2017 Q2	$341K	Buy	4,819 +3,150	+189%	+$210K	0.26%	65
2017 Q1	$113K	Buy	+1,669	New	+$117K	0.14%	44
2016 Q4	–	Sell	-1,669	Closed	-$132K	–	64
2016 Q3	$132K	Hold	1,669	–	–	0.1%	63
2016 Q2	$144K	Buy	1,669 +1	+0.1%	+$89	0.13%	42
2016 Q1	$143K	Hold	1,668	–	–	0.26%	30
2015 Q4	$168K	Sell	1,668 -29	-2%	-$3.02K	0.12%	24
2015 Q3	$166K	Buy	+1,697	New	+$188K	0.12%	19

Other funds holding GILD

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Tuttle Capital Management's GILD Position: Q4 2020 in Review

Tuttle Capital Management sold out of Gilead Sciences (GILD) in Q4 2020, closing a stake of 5,338 shares — an estimated $337K sold.

Tuttle Capital Management first reported a position in GILD in Q3 2015 and held it in 8 quarters. The position peaked at $341K in Q2 2017. 1,563 funds tracked by Wall St. Rank hold GILD as of Q4 2020.

Tuttle Capital Management reported no remaining Gilead Sciences position as of Q4 2020 after selling out during the quarter.
Tuttle Capital Management sold 5,338 Gilead Sciences shares in Q4 2020, an estimated $337K.
Tuttle Capital Management first reported a position in Gilead Sciences in Q3 2015 and held it in 8 quarters.
Tuttle Capital Management's Gilead Sciences position peaked at $341K in Q2 2017.
1,563 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2020.

Based on Tuttle Capital Management's 13F filing for Q4 2020, filed 20 Jan 2021.